Cart
sales@molnova.com
RGD peptide (GRGDNP) (TFA)
CAS No. ——
RGD peptide (GRGDNP) (TFA) ( —— )
Catalog No. M30010 CAS No. ——
RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRGD peptide (GRGDNP) (TFA)
-
NoteResearch use only, not for human use.
-
Brief DescriptionRGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
-
DescriptionRGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight728.63
-
Molecular FormulaC25H39F3N10O12
-
Purity>98% (HPLC)
-
SolubilityH2O : ≥ 50 mg/mL (68.62 mM);DMSO : ≥ 50 mg/mL (68.62 mM)
-
SMILES——
-
Chemical NameSequence:{Gly}{Arg}{Gly}{Asp}{Asn}{Pro}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Ruoslahti, E., and ?brink, B. Common principles in cell adhesion Experimental Cell Research 227, 1-11 (1996).
molnova catalog
related products
-
AGX51
AGX51 is an antagonist of inhibitor of DNA binding (ID) proteins. AGX51 treatment lead to pan-Id degradation, cell cycle arrest, and cell death.
-
Ethylamine
Ethylamine and glutamic acid are substrates of theanine synthetase.
-
APOL1-IN-1
APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.
